doi: 10.1002/1097-0142(19840915)54:6<961::aid-cncr2820540602>3.0.co;2-b.
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin
- PMID: 6467141
- DOI: 10.1002/1097-0142(19840915)54:6<961::aid-cncr2820540602>3.0.co;2-b
Item in Clipboard
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin
Cancer.
.
Abstract
Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single-agent Adriamycin (doxorubicin) after progression on 5-fluorouracil, and one partial response of 34 months was seen. It is concluded that 5-fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second-line agent.
Similar articles
-
Chemotherapy of malignant diffuse mesothelioma.Cancer. 1976 Mar;37(3):1265-74. doi: 10.1002/1097-0142(197603)37:3<1265::aid-cncr2820370306>3.0.co;2-q. Cancer. 1976. PMID: 1260651
-
Activity of pirarubicin (4'-0-tetrahydropyranyladriamycin) in malignant mesothelioma.Cancer. 1989 Mar 15;63(6):1084-91. doi: 10.1002/1097-0142(19890315)63:6<1084::aid-cncr2820630608>3.0.co;2-u. Cancer. 1989. PMID: 2917312
-
The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.Cancer. 1978 Oct;42(4):1692-6. doi: 10.1002/1097-0142(197810)42:4<1692::aid-cncr2820420406>3.0.co;2-y. Cancer. 1978. PMID: 709531
-
Therapeutic approaches in malignant mesothelioma.Cancer Treat Rev. 1977 Mar;4(1):13-23. doi: 10.1016/s0305-7372(77)80016-9. Cancer Treat Rev. 1977. PMID: 66990 Review. No abstract available.
-
Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma.Hepatogastroenterology. 2004 Jul-Aug;51(58):1073-83. Hepatogastroenterology. 2004. PMID: 15239250 Review.
Cited by
-
Investigational approaches for mesothelioma.Front Oncol. 2011 Aug 22;1:22. doi: 10.3389/fonc.2011.00022. eCollection 2011. Front Oncol. 2011. PMID: 22666659 Free PMC article.
-
Chemotherapy in malignant mesothelioma: a review.Cancer Chemother Pharmacol. 1991;28(5):319-30. doi: 10.1007/BF00685684. Cancer Chemother Pharmacol. 1991. PMID: 1914074 Review.
-
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.Ann Surg. 1996 Sep;224(3):288-94; discussion 294-6. doi: 10.1097/00000658-199609000-00005. Ann Surg. 1996. PMID: 8813257 Free PMC article. Clinical Trial.
-
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma.Cancers (Basel). 2020 Jun 6;12(6):1484. doi: 10.3390/cancers12061484. Cancers (Basel). 2020. PMID: 32517259 Free PMC article.
-
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.Br J Cancer. 2003 Jan 27;88(2):167-74. doi: 10.1038/sj.bjc.6600673. Br J Cancer. 2003. PMID: 12610498 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical